mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

BACKGROUND: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogani, Costanza, Bartalucci, Niccolò, Martinelli, Serena, Tozzi, Lorenzo, Guglielmelli, Paola, Bosi, Alberto, Vannucchi, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561413/
https://www.ncbi.nlm.nih.gov/pubmed/23382981
http://dx.doi.org/10.1371/journal.pone.0054826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561413/
https://www.ncbi.nlm.nih.gov/pubmed/23382981
http://dx.doi.org/10.1371/journal.pone.0054826

Ejemplares similares